Bristol-Myers Squibb (BMS) has agreed to sell its small-molecule active pharmaceutical ingredient (API) manufacturing facility in Swords, Ireland, to Seoul, South Korea-based contract development and ...
Bristol-Myers Squibb, which is shifting its focus toward biologics manufacturing, will unload an API plant in Ireland to a South Korean company that has aspirations of becoming a big deal in contract ...
Welcome to this week's FiercePharmaAsia report, which includes stories about an international antibiotic agreement, SK Bioteck's ambition to become a leading CDMO, Japanese firm JSR's acquisition of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results